Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas

Jenna Z. Marcus, Merieme Klobocista, Rouzan G. Karabakhtsian, Eric Prossnitz, Gary L. Goldberg, Gloria S. Huang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: This study aimed to identify the hormonal receptor status in uterine adenosarcoma (AS) and uterine AS with sarcomatous overgrowth (AS + SO), including those with high-grade histologic features (nuclear pleomorphism, atypical mitoses, necrosis), with or without heterologous elements. Estrogen receptor (ER) status, including estrogen receptor α (ERα), estrogen receptor β (ERβ), and G protein-coupled estrogen receptor (GPER), and progesterone receptor (PgR) status were examined. Methods: From August 2001 to November 2013, 11 patients with histologic diagnosis of uterine AS were identified. Tumor tissue sections were stained for ERα, ERβ, GPER, and PgR and examined both for percentage of overall cells stained and for intensity of staining. Descriptive statistics were calculated using clinicopathologic data abstracted from the medical record. Results: Eight cases of AS and 3 cases of AS with high-grade features were identified. Seven of 8 tumor samples of AS showed strong or moderate intensity immunostaining for ERα; all AS + SO tumor samples showed minimal to no immunoreactivity for ERα. There was a significant decrease in ERα H scores in high-grade tumors when compared with AS (P = 0.01). Lower PgR H scores were observed in high-grade tumors compared with those in AS (P = 0.04). Estrogen receptor β immunostaining was variable, and GPER immunostaining was absent in the majority of tumor samples. Conclusions: Higher expression of ERα and PgR was observed in AS when compared with those with AS + SO and high-grade features. Both tumor subtypes showed similar levels of ERβ and GPER expression, although significant differences in ERβ and GPER expression were not detected. In contrast to our previous findings in uterine carcinosarcoma, ERs ERβ and GPER do not seem to play a significant role in AS in this study.

Original languageEnglish (US)
Pages (from-to)500-504
Number of pages5
JournalInternational Journal of Gynecological Cancer
Volume28
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Adenosarcoma
Gonadal Steroid Hormones
Estrogen Receptors
G-Protein-Coupled Receptors
Progesterone Receptors
Neoplasms
Adenosarcoma of the uterus
Carcinosarcoma
Mitosis
Medical Records

Keywords

  • Estrogen receptor status
  • Estrogen receptor α
  • Estrogen receptor β
  • G protein-coupled estrogen receptor
  • Progesterone receptor
  • Uterine adenosarcoma

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas. / Marcus, Jenna Z.; Klobocista, Merieme; Karabakhtsian, Rouzan G.; Prossnitz, Eric; Goldberg, Gary L.; Huang, Gloria S.

In: International Journal of Gynecological Cancer, Vol. 28, No. 3, 01.03.2018, p. 500-504.

Research output: Contribution to journalArticle

Marcus, Jenna Z. ; Klobocista, Merieme ; Karabakhtsian, Rouzan G. ; Prossnitz, Eric ; Goldberg, Gary L. ; Huang, Gloria S. / Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas. In: International Journal of Gynecological Cancer. 2018 ; Vol. 28, No. 3. pp. 500-504.
@article{58217cba69c945609f3f1aa357ddd45d,
title = "Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas",
abstract = "Objective: This study aimed to identify the hormonal receptor status in uterine adenosarcoma (AS) and uterine AS with sarcomatous overgrowth (AS + SO), including those with high-grade histologic features (nuclear pleomorphism, atypical mitoses, necrosis), with or without heterologous elements. Estrogen receptor (ER) status, including estrogen receptor α (ERα), estrogen receptor β (ERβ), and G protein-coupled estrogen receptor (GPER), and progesterone receptor (PgR) status were examined. Methods: From August 2001 to November 2013, 11 patients with histologic diagnosis of uterine AS were identified. Tumor tissue sections were stained for ERα, ERβ, GPER, and PgR and examined both for percentage of overall cells stained and for intensity of staining. Descriptive statistics were calculated using clinicopathologic data abstracted from the medical record. Results: Eight cases of AS and 3 cases of AS with high-grade features were identified. Seven of 8 tumor samples of AS showed strong or moderate intensity immunostaining for ERα; all AS + SO tumor samples showed minimal to no immunoreactivity for ERα. There was a significant decrease in ERα H scores in high-grade tumors when compared with AS (P = 0.01). Lower PgR H scores were observed in high-grade tumors compared with those in AS (P = 0.04). Estrogen receptor β immunostaining was variable, and GPER immunostaining was absent in the majority of tumor samples. Conclusions: Higher expression of ERα and PgR was observed in AS when compared with those with AS + SO and high-grade features. Both tumor subtypes showed similar levels of ERβ and GPER expression, although significant differences in ERβ and GPER expression were not detected. In contrast to our previous findings in uterine carcinosarcoma, ERs ERβ and GPER do not seem to play a significant role in AS in this study.",
keywords = "Estrogen receptor status, Estrogen receptor α, Estrogen receptor β, G protein-coupled estrogen receptor, Progesterone receptor, Uterine adenosarcoma",
author = "Marcus, {Jenna Z.} and Merieme Klobocista and Karabakhtsian, {Rouzan G.} and Eric Prossnitz and Goldberg, {Gary L.} and Huang, {Gloria S.}",
year = "2018",
month = "3",
day = "1",
doi = "10.1097/IGC.0000000000001183",
language = "English (US)",
volume = "28",
pages = "500--504",
journal = "International Journal of Gynecological Cancer",
issn = "1048-891X",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Female Sex Hormone Receptor Profiling in Uterine Adenosarcomas

AU - Marcus, Jenna Z.

AU - Klobocista, Merieme

AU - Karabakhtsian, Rouzan G.

AU - Prossnitz, Eric

AU - Goldberg, Gary L.

AU - Huang, Gloria S.

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Objective: This study aimed to identify the hormonal receptor status in uterine adenosarcoma (AS) and uterine AS with sarcomatous overgrowth (AS + SO), including those with high-grade histologic features (nuclear pleomorphism, atypical mitoses, necrosis), with or without heterologous elements. Estrogen receptor (ER) status, including estrogen receptor α (ERα), estrogen receptor β (ERβ), and G protein-coupled estrogen receptor (GPER), and progesterone receptor (PgR) status were examined. Methods: From August 2001 to November 2013, 11 patients with histologic diagnosis of uterine AS were identified. Tumor tissue sections were stained for ERα, ERβ, GPER, and PgR and examined both for percentage of overall cells stained and for intensity of staining. Descriptive statistics were calculated using clinicopathologic data abstracted from the medical record. Results: Eight cases of AS and 3 cases of AS with high-grade features were identified. Seven of 8 tumor samples of AS showed strong or moderate intensity immunostaining for ERα; all AS + SO tumor samples showed minimal to no immunoreactivity for ERα. There was a significant decrease in ERα H scores in high-grade tumors when compared with AS (P = 0.01). Lower PgR H scores were observed in high-grade tumors compared with those in AS (P = 0.04). Estrogen receptor β immunostaining was variable, and GPER immunostaining was absent in the majority of tumor samples. Conclusions: Higher expression of ERα and PgR was observed in AS when compared with those with AS + SO and high-grade features. Both tumor subtypes showed similar levels of ERβ and GPER expression, although significant differences in ERβ and GPER expression were not detected. In contrast to our previous findings in uterine carcinosarcoma, ERs ERβ and GPER do not seem to play a significant role in AS in this study.

AB - Objective: This study aimed to identify the hormonal receptor status in uterine adenosarcoma (AS) and uterine AS with sarcomatous overgrowth (AS + SO), including those with high-grade histologic features (nuclear pleomorphism, atypical mitoses, necrosis), with or without heterologous elements. Estrogen receptor (ER) status, including estrogen receptor α (ERα), estrogen receptor β (ERβ), and G protein-coupled estrogen receptor (GPER), and progesterone receptor (PgR) status were examined. Methods: From August 2001 to November 2013, 11 patients with histologic diagnosis of uterine AS were identified. Tumor tissue sections were stained for ERα, ERβ, GPER, and PgR and examined both for percentage of overall cells stained and for intensity of staining. Descriptive statistics were calculated using clinicopathologic data abstracted from the medical record. Results: Eight cases of AS and 3 cases of AS with high-grade features were identified. Seven of 8 tumor samples of AS showed strong or moderate intensity immunostaining for ERα; all AS + SO tumor samples showed minimal to no immunoreactivity for ERα. There was a significant decrease in ERα H scores in high-grade tumors when compared with AS (P = 0.01). Lower PgR H scores were observed in high-grade tumors compared with those in AS (P = 0.04). Estrogen receptor β immunostaining was variable, and GPER immunostaining was absent in the majority of tumor samples. Conclusions: Higher expression of ERα and PgR was observed in AS when compared with those with AS + SO and high-grade features. Both tumor subtypes showed similar levels of ERβ and GPER expression, although significant differences in ERβ and GPER expression were not detected. In contrast to our previous findings in uterine carcinosarcoma, ERs ERβ and GPER do not seem to play a significant role in AS in this study.

KW - Estrogen receptor status

KW - Estrogen receptor α

KW - Estrogen receptor β

KW - G protein-coupled estrogen receptor

KW - Progesterone receptor

KW - Uterine adenosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85042857146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042857146&partnerID=8YFLogxK

U2 - 10.1097/IGC.0000000000001183

DO - 10.1097/IGC.0000000000001183

M3 - Article

VL - 28

SP - 500

EP - 504

JO - International Journal of Gynecological Cancer

JF - International Journal of Gynecological Cancer

SN - 1048-891X

IS - 3

ER -